Labcorp Holdings Inc. (LH)
Labcorp Stock Gains From Biopharma Business Amid FX Woe
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Should You Continue to Retain LH Stock in Your Portfolio?
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
Labcorp says it could ramp up mpox testing capacity
Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.
